FDA Approves Moderna's New Lower-Dose COVID-19 Vaccine
The FDA has approved Moderna’s new lower-dose COVID-19 vaccine, mNexspike, offering tailored protection for high-risk populations. Learn more about this innovative development in COVID-19 immunization.
The U.S. Food and Drug Administration (FDA) has officially authorized a new, lower-dose version of Moderna's COVID-19 vaccine, designed to enhance protection in high-risk populations. This innovative vaccine, known as mNexspike, is a significant advancement in coronavirus immunization technology. It features a dose that is approximately one-fifth of the standard amount used in Moderna's Spikevax, achieved through a targeted design that aims to provoke a more focused immune response. Importantly, this new vaccine is not intended to replace the existing Moderna COVID-19 shot but rather to serve as an additional option.
mNexspike is approved specifically for individuals aged 65 and older who have been previously vaccinated with any COVID-19 vaccine, as well as for those aged 12 to 64 who possess at least one underlying health condition that increases their risk of severe illness from COVID-19. This limited authorization aligns with the approval of other targeted vaccines like Novavax's last month.
In the upcoming fall, Moderna plans to offer both Spikevax and mNexspike, providing flexibility in COVID-19 vaccination strategies. The current primary vaccine remains widely accessible for individuals aged 6 months and older without restrictions.
Moderna’s CEO, Stephane Bancel, emphasized that the new lower-dose vaccine is a valuable addition to the arsenal of tools available to protect high-risk groups against severe COVID-19 outcomes. The approval marks an important step in refining vaccine strategies to better address the ongoing pandemic.
For more details, visit source.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
New Insights into How the Brain Constructs Neural Networks for Motor Memories
Recent research reveals how the brain constructs and refines neural networks for motor memories, offering new insights into movement learning and potential therapies for Parkinson's disease.
Uncovering Hidden Genetic Risks in Hispanic/Latino Communities: Lessons from a Dominican Heart Mutation
A groundbreaking study reveals the presence of a critical heart-related genetic mutation among Dominican Americans, highlighting the importance of inclusive, ancestry-aware research in advancing precision medicine.
Impact of Restricted Public Health Data on Flu Forecasting and Public Safety
Limiting access to vital public health data hampers influenza forecasting and disease response efforts. New research highlights the risks of data suppression for public safety and health decision-making.
GERD and Its Potential Link to Ear Disorders Including Tinnitus and Meniere Disease
Emerging evidence links Gastroesophageal Reflux Disease (GERD) to increased risks of ear disorders such as tinnitus, Meniere disease, and hearing loss. New research highlights the potential causal relationship and its implications for ear health management.